BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 35372372)

  • 1. Increased CDCA2 Level Was Related to Poor Prognosis in Hepatocellular Carcinoma and Associated With Up-Regulation of Immune Checkpoints.
    Tang M; Liao M; Ai X; He G
    Front Med (Lausanne); 2021; 8():773724. PubMed ID: 35372372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell division cycle associated 2 (CDCA2) upregulation promotes the progression of hepatocellular carcinoma in a p53-dependant manner.
    Wang J; Liu X; Chu H; Chen J
    PeerJ; 2022; 10():e13535. PubMed ID: 35694386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
    Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
    Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
    [No Abstract]   [Full Text] [Related]  

  • 4. Identification of CDCA2 as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma.
    Yu Z; Zhang Y; Shao S; Liu Q; Li Y; Du X; Zhang K; Zhang M; Yuan H; Yuan Q; Liu T; Gao Y; Wang Y; Hong W; Han T
    Front Oncol; 2021; 11():755814. PubMed ID: 34660326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
    Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
    World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased E2F2 predicts poor prognosis in patients with HCC based on TCGA data.
    Zeng Z; Cao Z; Tang Y
    BMC Cancer; 2020 Oct; 20(1):1037. PubMed ID: 33115417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of
    Yang P; Liu H; Li Y; Gao Q; Chen X; Chang J; Li Y; Chen S; Dong R; Wu H; Liu C; Liu G
    Front Genet; 2022; 13():959832. PubMed ID: 36299588
    [No Abstract]   [Full Text] [Related]  

  • 8. Over-expression of RRM2 predicts adverse prognosis correlated with immune infiltrates: A potential biomarker for hepatocellular carcinoma.
    Qin Z; Xie B; Qian J; Ma X; Zhang L; Wei J; Wang Z; Fan L; Zhu Z; Qian Z; Yin H; Zhu F; Tan Y
    Front Oncol; 2023; 13():1144269. PubMed ID: 37056349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1) predicts poor survival in patients with hepatocellular carcinoma.
    Jiang W; Wu T; Shi X; Xu J
    Bioengineered; 2021 Dec; 12(1):7941-7949. PubMed ID: 34612781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDCA2 protects against oxidative stress by promoting BRCA1-NRF2 signaling in hepatocellular carcinoma.
    Wang S; Cao K; Liao Y; Zhang W; Zheng J; Li X; Huang M; Zhong Y; Hu X; Chen D; Wang Y
    Oncogene; 2021 Jun; 40(25):4368-4383. PubMed ID: 34103686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDCA2 Promotes HCC Cells Development via AKT-mTOR Pathway.
    Li K; Fan T; Shi Z; Jiang H
    Anal Cell Pathol (Amst); 2022; 2022():9912254. PubMed ID: 36588796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDCA2 triggers in vivo and in vitro proliferation of hepatocellular carcinoma by activating the AKT/CCND1 signaling.
    Li J; Chen Y; Wang X; Wang C
    J BUON; 2021; 26(3):882-888. PubMed ID: 34268949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of Ribosomal Protein S6 Kinase A4 (RPS6KA4) Predicts a Poor Prognosis in Hepatocellular Carcinoma Patients: A Study Based on TCGA Samples.
    Lu Y; Ren X; Zhou C; Chen H; Fan Y; Wang C
    Comb Chem High Throughput Screen; 2022; 25(13):2165-2179. PubMed ID: 35232347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma.
    Yu B; Ding Y; Liao X; Wang C; Wang B; Chen X
    Dig Dis Sci; 2019 Oct; 64(10):2878-2892. PubMed ID: 30949905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification METTL18 as a Potential Prognosis Biomarker and Associated With Immune Infiltrates in Hepatocellular Carcinoma.
    Li TH; Qin C; Zhao BB; Cao HT; Yang XY; Wang YY; Li ZR; Zhou XT; Wang WB
    Front Oncol; 2021; 11():665192. PubMed ID: 34123827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpressed PAQR4 predicts poor overall survival and construction of a prognostic nomogram based on PAQR family for hepatocellular carcinoma.
    Qu C; Ma T; Yan X; Li X; Li Y
    Math Biosci Eng; 2022 Jan; 19(3):3069-3090. PubMed ID: 35240821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDCA2 promotes lung adenocarcinoma cell proliferation and predicts poor survival in lung adenocarcinoma patients.
    Shi R; Zhang C; Wu Y; Wang X; Sun Q; Sun J; Xia W; Dong G; Wang A; Jiang F; Xu L
    Oncotarget; 2017 Mar; 8(12):19768-19779. PubMed ID: 28423619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of NOP58 as a Prognostic Marker in Hepatocellular Carcinoma: A TCGA Data-Based Analysis.
    Wang J; Huang R; Huang Y; Chen Y; Chen F
    Adv Ther; 2021 Jun; 38(6):3342-3361. PubMed ID: 34014550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exonuclease 1 is a Potential Diagnostic and Prognostic Biomarker in Hepatocellular Carcinoma.
    Ma J; Jin J; Lu H; Zhang J; Li Y; Cai X
    Front Mol Biosci; 2022; 9():889414. PubMed ID: 35769911
    [No Abstract]   [Full Text] [Related]  

  • 20. High Expression of POGK Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma.
    Xu W; Huang Y; Mei Y; Zhang Y; Luo Q; Zhu S; Peng L; Gao Z; Liu Y; Li J
    Curr Oncol; 2022 Nov; 29(11):8650-8667. PubMed ID: 36421335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.